Stocks Up as Bullar...
Health Care: Drugs
NPS Pharmaceuticals Inc (NPSP: NASDAQ)
$14.53 0.42 | 2.98%
05/21/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 130.64M | 101.64M | 89.41M | 84.15M |
| Cost of Sales | 0.00 | 2.58M | 75.00K | 827.00K |
| Gross Operating Profit | 130.64M | 99.06M | 89.34M | 83.32M |
| Selling, General, and Administrative Expenses | 36.93M | 24.23M | 18.95M | 20.10M |
| Research & Development | 94.84M | 73.83M | 60.81M | 35.34M |
| Operating Income before D & A (EBITDA) | -1.12M | 1.01M | 9.57M | 27.88M |
| Depreciation & Amortization | 1.08M | 462.00K | 137.00K | 154.00K |
| Interest Income | 292.00K | 321.00K | 418.00K | 1.71M |
| Other Income - Net | 295.00K | 621.00K | 4.79M | 3.61M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -1.62M | 1.49M | 14.64M | 33.02M |
| Interest Expense | 18.20M | 37.74M | 45.13M | 52.63M |
| Pre-Tax Income | -19.82M | -36.25M | -30.49M | -19.61M |
| Income Taxes | 0.00 | 18.00K | 1.09M | -1.74M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -18.74M | -36.27M | -31.44M | -17.86M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -18.74M | -36.27M | -31.44M | -17.86M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -18.74M | -36.27M | -31.44M | -17.86M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-18.74M | -36.27M | -31.44M | -17.84M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -18.74M | -36.27M | -31.44M | -17.86M |
| Basic EPS from Continuing Ops. | -0.22 | -0.45 | -0.54 | -0.37 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.22 | -0.45 | -0.54 | -0.37 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.22 | -0.45 | -0.54 | -0.37 |
| Basic Normalized Net Income/Share | -0.22 | -0.45 | -0.54 | -0.37 |
| EPS fr Continuing Ops. | -0.22 | -0.45 | -0.54 | -0.37 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.22 | -0.45 | -0.54 | -0.37 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.22 | -0.45 | -0.54 | -0.37 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.22 | -0.45 | -0.54 | -0.37 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with NPSP
- Portfolio NameUser Type
- UserMy Watch List
- UserJaq Le Blanc 09/30
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Under-$10 Moving Hig...
- Userchinahound2
- ContributorBreakout Stocks Of The Week...
- Usersalvatore Portfolio 1
- UserRocket Stocks for the week ...
Latest NPSP Headlines from TheStreet
- NPS Pharmaceuticals Inc Stock Upgraded (NPSP) 05.14.13 | 05:05 am
- Cramer's Top Stock Picks: WM VRTX SRPT NPSP DR 04.03.13 | 06:04 am
- Cramer's 'Mad Money' Recap: The Winning Formula 04.02.13 | 08:04 pm
- Mad Money Uncovered: Orphan Drug Stocks
03.20.13 | 12:03 pm - Cramer's Top Stock Picks: HTZ NPSP GLD 03.20.13 | 06:03 am
- Cramer's 'Mad Money' Recap: Be an Informed Skeptic 03.19.13 | 08:03 pm
- Tuesday Trend Continues: Morning Movers 03.19.13 | 10:03 am
- Morning Briefing: 10 Things You Should Know 03.19.13 | 05:03 am
- NPS Pharma Buys Back Worldwide Rights To Short Bowel Syndrome Drug 03.19.13 | 02:03 am
- Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma 01.18.13 | 08:01 am
Press Releases for NPSP
- NPS Pharmaceuticals And Takeda Revise Agreements And NPS Re-Gains Full Worldwide Rights To Teduglutide And Recombinant Human Parathyroid Hormone 1-84 - Business Wire 03.19.13 | 02:03 am
- NPS Pharmaceuticals To Present At Barclays Capital Global Healthcare Conference - Business Wire 03.05.13 | 08:03 am
- NPS Pharmaceuticals Observes Rare Disease Day 2013 And Celebrates 30th Anniversary Of National Organization For Rare Disorders - Business Wire 02.28.13 | 08:02 am
- NPS Pharmaceuticals Reports 2012 Financial Results And 2013 Guidance - Business Wire 02.21.13 | 04:02 pm
- NPS Pharmaceuticals To Present At RBC Capital Markets Healthcare Conference - Business Wire 02.19.13 | 04:02 pm
- NPS Pharmaceuticals To Report 2012 Financial Results - Business Wire 02.13.13 | 08:02 am
- NPS Pharmaceuticals To Present At Upcoming Conferences - Business Wire 02.05.13 | 04:02 pm
- New Peer-reviewed Publication Offers Guidance For Integrating Gattex® (Teduglutide [rDNA Origin]) For Injection Into Management Of Short Bowel Syndrome - Business Wire 01.30.13 | 08:01 am
- NPS Pharmaceuticals To Present At J.P. Morgan Healthcare Conference - Business Wire 01.03.13 | 08:01 am
- NPS Pharmaceuticals To Host Conference Call To Discuss FDA Approval Of Gattex® (teduglutide [rDNA Origin]) For Injection For The Treatment Of Adult Short Bowel Syndrome - Business Wire 01.02.13 | 08:01 am
Partner Headlines for NPSP
- Current Prime Pharma Entries In Anticipation Of Prime Time Exits - Seeking Alpha 11.06.12 | 09:11 am
- Benzinga Mid-Day Market Update - Benzinga 10.16.12 | 01:10 pm
- 3 Best Biotech Stocks For This Week (Part VI) - Seeking Alpha 10.16.12 | 08:10 am
- NPS Pharmaceuticals: Buy If There Is A Dip - Seeking Alpha 10.14.12 | 08:10 am
- UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight on Portfolio Quality - Benzinga 10.04.12 | 01:10 pm
- NPS Pharma Says Gattex Meeting October 16th - Benzinga 08.21.12 | 08:08 am
- 7 High-Growth Small-Cap Stocks With Strong Buy Ratings - Seeking Alpha 07.28.12 | 09:07 am
- Amylin Pharmaceutical POPS 8.9% with 4 Stocks Hitting 52-Week Highs - Wall St. Cheat Sheet 07.03.12 | 10:07 am
- 10 Biotech Stocks With Strong Corporate Governance - Seeking Alpha 01.18.12 | 09:01 am
- 6 Biotechs That Could See Huge Gains (Like Inhibitex) - Seeking Alpha 11.11.11 | 09:11 am
